Skip to content

Monopar Therapeutics MNPR Cash Flow Statement

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$3.89M+25.1%-$5.2M-51.3%-$3.44M-40.1%-$2.45M+6.5%-$2.62M+76.0%
$1.69M+53.3%$1.1M+0.4%$1.1M-14.1%$1.28M-5.6%$1.36M+386%
-$3.47M-3.1%-$3.37M-61.2%-$2.09M-94.0%-$1.08M+81.0%-$5.66M-183%
-$5.58M+91.0%-$62.19M-2,825%-$2.13M-279%$1.19M+464%-$325.83K+97.7%
-$200.2K$0-100%$92.39M+29,260%-$316.85K-174%-$115.68K-100%
-$9.29M$88.18M+42,194%-$209.47K+96.6%-$6.1M-115%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Monopar Therapeutics generate?
Monopar Therapeutics (MNPR) generated -$10.0M in operating cash flow over the trailing twelve months.
Where does Monopar Therapeutics's cash flow data come from?
Every line is extracted from Monopar Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.